MX9303771A - Proteina viral icp27 del virus vhs-2, proceso para su preparacion y composicion de vacuna que la incluye. - Google Patents

Proteina viral icp27 del virus vhs-2, proceso para su preparacion y composicion de vacuna que la incluye.

Info

Publication number
MX9303771A
MX9303771A MX9303771A MX9303771A MX9303771A MX 9303771 A MX9303771 A MX 9303771A MX 9303771 A MX9303771 A MX 9303771A MX 9303771 A MX9303771 A MX 9303771A MX 9303771 A MX9303771 A MX 9303771A
Authority
MX
Mexico
Prior art keywords
virus
preparation
vaccine
composition
vhs
Prior art date
Application number
MX9303771A
Other languages
English (en)
Inventor
Moncef Slaqui
Pietro Pala
Marguerite Koutsoukos
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of MX9303771A publication Critical patent/MX9303771A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La presente invención se relaciona con la proteína primaria viral del VHS-2 inmediata, reconocida por las células linfocitos T citolíticos (LTC) en humanos, los métodos para la preparación de la misma y el uso en vacunas.
MX9303771A 1992-06-25 1993-06-23 Proteina viral icp27 del virus vhs-2, proceso para su preparacion y composicion de vacuna que la incluye. MX9303771A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9213559A GB9213559D0 (en) 1992-06-25 1992-06-25 Vaccines

Publications (1)

Publication Number Publication Date
MX9303771A true MX9303771A (es) 1994-05-31

Family

ID=10717757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303771A MX9303771A (es) 1992-06-25 1993-06-23 Proteina viral icp27 del virus vhs-2, proceso para su preparacion y composicion de vacuna que la incluye.

Country Status (11)

Country Link
EP (1) EP0649470A1 (es)
JP (1) JPH07508648A (es)
KR (1) KR950702244A (es)
CN (1) CN1092812A (es)
AU (2) AU676166B2 (es)
CA (1) CA2138996A1 (es)
GB (1) GB9213559D0 (es)
MX (1) MX9303771A (es)
NZ (1) NZ253138A (es)
TW (1) TW269635B (es)
WO (1) WO1994000575A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE505542T1 (de) 1998-02-05 2011-04-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung
ES2337429T3 (es) * 1999-10-11 2010-04-23 Institut Pasteur Vectores lentivirales para la preparacion de composiciones inmunoterapeuticas.
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection

Also Published As

Publication number Publication date
GB9213559D0 (en) 1992-08-12
AU4326493A (en) 1994-01-24
KR950702244A (ko) 1995-06-19
JPH07508648A (ja) 1995-09-28
WO1994000575A1 (en) 1994-01-06
EP0649470A1 (en) 1995-04-26
TW269635B (es) 1996-02-01
NZ253138A (en) 1995-10-26
AU1785597A (en) 1997-06-19
AU676166B2 (en) 1997-03-06
CN1092812A (zh) 1994-09-28
CA2138996A1 (en) 1994-01-06

Similar Documents

Publication Publication Date Title
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ES2136088T3 (es) Compuestos inmunogenos con efecto principalmente anti-citoquina, procedimiento de preparacion, composiciones farmaceuticas y kits que los contienen.
ES2081102T3 (es) Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.
ES2134797T3 (es) Peptidos y fragmentos de peptidos terapeuticamente utiles.
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
AR025502A1 (es) Composicion de vacuna adecuada para usar en el tratamiento o la profilaxis de infecciones de virus del papiloma humano e infecciones de virus del herpes simple.
ES2035818T3 (es) Mutantes de delecion de la timidin-kinasa del virus del herpes bovino-1, vacunas contra la rinotraqueitis bovina infecciosa que los contienen y metodos para su produccion y uso.
TR200102313T2 (tr) Antiviral maddeler olarak (1R, SíS)-4-(6-amino-9H-purin-9-il)-2-siklopenten-1-metanoln mono-, di ve tri-fosfat esterleri ve fosforamidatlarì
BR9105737A (pt) Processo para reduzir a contaminacao de um produto de amplificacao,conjunto para uso em um tipo de procedimento de amplificacao e processo para amplificar uma sequencia de amplificacao de uma sequencia-alvo
GB2255093A (en) Hiv-1 core protein fragments
DK0588578T3 (da) Immunogener
ES2051678T1 (es) Derivados de 5-oxo-l-prolina y uso farmaceutico de los mismos.
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
ITMI913092A1 (it) Vaccino di poxvirus ricombinante del virus del morbillo
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
AR021414A1 (es) Formulaciones conteniendo particulas semejantes a virus como inmunopotenciadores por via mucosal
MX9303771A (es) Proteina viral icp27 del virus vhs-2, proceso para su preparacion y composicion de vacuna que la incluye.
DK0553294T3 (da) Fremstillingen af sammensætninger til behandlingen af celleproliferationssygdomme
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
MX9101275A (es) Proteina gp160 del virus de inmunodeficiencia humana y composiciones para vacuna que contiene a la misma o a su derivado
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
ES2177535T3 (es) Vacunas contra protozoos intestinales.
MX9401172A (es) Derivados fluorados de 4-aminoandrostadienona, procesamiento para su preparacion y composiciones farmaceuticas que los contienen.